{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:30:37Z","timestamp":1788395437781,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Key Program for the National Natural Science Foundation of China","award":["82304901"],"award-info":[{"award-number":["82304901"]}]},{"name":"Key Program for the National Natural Science Foundation of China","award":["82202034"],"award-info":[{"award-number":["82202034"]}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2021A1515110430"],"award-info":[{"award-number":["2021A1515110430"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Scientific Research Project Program of Sichuan Medical Association","award":["S20038"],"award-info":[{"award-number":["S20038"]}]},{"name":"Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome"},{"name":"Guangzhou Science and Technology Plan Project","award":["2023A03J0262"],"award-info":[{"award-number":["2023A03J0262"]}]},{"name":"Guangzhou Science and Technology Plan Project","award":["2024A03J0991"],"award-info":[{"award-number":["2024A03J0991"]}]},{"name":"Guangzhou Science and Technology Plan Project","award":["2024A04J4325"],"award-info":[{"award-number":["2024A04J4325"]}]},{"name":"Foundation of Guangdong Second Provincial General Hospital","award":["YN2023-001"],"award-info":[{"award-number":["YN2023-001"]}]},{"name":"Foundation of Guangdong Second Provincial General Hospital","award":["TJGC-2023002"],"award-info":[{"award-number":["TJGC-2023002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-024-01444-9","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T15:02:19Z","timestamp":1729695739000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment-free remission after discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"15","author":[{"given":"Zhenxiang","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangmin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"issue":"15","key":"1444_CR1","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1158\/1078-0432.CCR-19-2460","volume":"26","author":"Z Yin","year":"2020","unstructured":"Yin Z, Huang G, Gu C, Liu Y, Yang J, Fei J. Discovery of berberine that targetedly induces autophagic degradation of both BCR-ABL and BCR-ABL T315I through recruiting LRSAM1 for overcoming imatinib resistance. Clin Cancer Res. 2020;26(15):4040\u201353.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1444_CR2","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994\u20131004.","journal-title":"N Engl J Med"},{"issue":"14","key":"1444_CR3","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031\u20137.","journal-title":"N Engl J Med"},{"issue":"5","key":"1444_CR4","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044\u201354.","journal-title":"Leukemia"},{"issue":"12","key":"1444_CR5","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1182\/bloodadvances.2019001329","volume":"4","author":"C Vener","year":"2020","unstructured":"Vener C, Banzi R, Ambrogi F, Ferrero A, Saglio G, Pravettoni G, Sant M. First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis. Blood Adv. 2020;4(12):2723\u201335.","journal-title":"Blood Adv"},{"issue":"24","key":"1444_CR6","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM, Investigators EN. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"1444_CR7","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Sau\u00dfele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966\u201384.","journal-title":"Leukemia"},{"issue":"11","key":"1444_CR8","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/ajh.26686","volume":"97","author":"HM Kantarjian","year":"2022","unstructured":"Kantarjian HM, Jabbour E, Deininger M, Abruzzese E, Apperley J, Cortes J, Chuah C, DeAngelo DJ, DiPersio J, Hochhaus A, Lipton J, Nicolini FE, Pinilla-Ibarz J, Rea D, Rosti G, Rousselot P, Shah NP, Talpaz M, Srivastava S, Ren X, Mauro M. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. Am J Hematol. 2022;97(11):1419\u201326.","journal-title":"Am J Hematol"},{"issue":"3","key":"1444_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","volume":"37","author":"A Hochhaus","year":"2023","unstructured":"Hochhaus A, R\u00e9a D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, Apperley JF, Lomaia E, Voloshin S, Turkina A, Kim DW, Abdo A, Fogliatto LM, le Coutre P, Sasaki K, Kim DDH, Saussele S, Annunziata M, Chaudhri N, Chee L, Garc\u00eda-Guti\u00e9rrez V, Kapoor S, Allepuz A, Quenet S, B\u00e9doucha V, Mauro MJ. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37(3):617\u201326.","journal-title":"Leukemia"},{"issue":"6","key":"1444_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrclinonc.2017.31","volume":"14","author":"V Prasad","year":"2017","unstructured":"Prasad V, De Jes\u00fas K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017;14(6):381\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"1444_CR11","doi-asserted-by":"crossref","unstructured":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013, 121 (22), 4439\u201342.","DOI":"10.1182\/blood-2013-03-490003"},{"issue":"11","key":"1444_CR12","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P. Filmc, Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncology. 2010;11(11):1029\u201335.","journal-title":"Lancet Oncology"},{"issue":"12","key":"1444_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.47950","volume":"6","author":"AN Winn","year":"2023","unstructured":"Winn AN, Atallah E, Cortes J, Deininger MWN, Kota V, Larson RA, Moore JO, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Shah NP, Thompson JE, Flynn KE. Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia. JAMA Netw Open. 2023;6(12): e2347950.","journal-title":"JAMA Netw Open"},{"issue":"23","key":"1444_CR14","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1182\/bloodadvances.2020003235","volume":"5","author":"C Pavlovsky","year":"2021","unstructured":"Pavlovsky C, Abello Polo V, Pagnano K, Varela AI, Agudelo C, Bianchini M, Boquimpani C, Centrone R, Conchon M, Delgado N, Funke V, Giere I, Luise I, Meillon L, Moiraghi B, Navarro JR, Pilleux L, Prado AI, Undurraga S, Cortes J. Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel. Blood Adv. 2021;5(23):4855\u201363.","journal-title":"Blood Adv"},{"issue":"4","key":"1444_CR15","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/bjh.17447","volume":"193","author":"DDH Kim","year":"2021","unstructured":"Kim DDH, Novitzky-Basso I, Kim TS, Atenafu EG, Forrest D, Savoie L, Bence-Bruckler I, Keating MM, Busque L, Delage R, Xenocostas A, Liew E, Paulson K, Stockley T, Laneuville P, Lipton JH, Kamel-Reid S, Leber B. Optimal duration of imatinib treatment\/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial. Br J Haematol. 2021;193(4):779\u201391.","journal-title":"Br J Haematol"},{"issue":"3","key":"1444_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/bjh.16408","volume":"189","author":"S Dulucq","year":"2020","unstructured":"Dulucq S, Astrugue C, Etienne G, Mahon FX, Benard A. Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years. Br J Haematol. 2020;189(3):452\u201368.","journal-title":"Br J Haematol"},{"key":"1444_CR17","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3389\/fonc.2019.00372","volume":"9","author":"KK Chen","year":"2019","unstructured":"Chen KK, Du TF, Xiong PS, Fan GH, Yang W. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia with losing major molecular response as a definition for molecular relapse: a systematic review and meta-analysis. Front Oncol. 2019;9:372.","journal-title":"Front Oncol"},{"issue":"6","key":"1444_CR18","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s12185-019-02744-5","volume":"110","author":"J Kim","year":"2019","unstructured":"Kim J, Park J, Moon Y, Choi SJ, Lim JH, Lee MH, Cho J. Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: a systematic review and meta-analysis. Int J Hematol. 2019;110(6):683\u20139.","journal-title":"Int J Hematol"},{"key":"1444_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"issue":"9","key":"1444_CR20","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712\u20136.","journal-title":"ANZ J Surg"},{"key":"1444_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials"},{"issue":"15","key":"1444_CR22","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1016\/j.ejca.2013.06.018","volume":"49","author":"N Thielen","year":"2013","unstructured":"Thielen N, van der Holt B, Cornelissen JJ, Verhoef GEG, Gussinklo T, Biemond BJ, Daenen SMG, Deenik W, Kooy RV, Petersen E, Smit WM, Valk PJM, Ossenkoppele GJ, Janssen J. Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). Eur J Cancer. 2013;49(15):3242\u20136.","journal-title":"Eur J Cancer"},{"issue":"6","key":"1444_CR23","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/ajh.23427","volume":"88","author":"SE Lee","year":"2013","unstructured":"Lee SE, Choi SY, Bang JH, Kim SH, Jang EJ, Byeun JY, Park JE, Jeon HR, Oh YJ, Kim HJ, Kim YK, Park JS, Jeong SH, Kim SH, Zang DY, Oh S, Koo DH, Kim H, Do YR, Kwak JY, Kim JA, Kim DY, Mun YC, Mauro MJ, Kim DW. Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib. Am J Hematol. 2013;88(6):449\u201354.","journal-title":"Am J Hematol"},{"key":"1444_CR24","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1182\/blood-2021-145483","volume":"138","author":"C Yoshida","year":"2021","unstructured":"Yoshida C, Yamaguchi H, Doki N, Murai K, Iino M, Hatta Y, Onizuka M, Yokose N, Fujimaki K, Hagihara M, Oshikawa G, Murayama K, Kumagai T, Kimura S, Muto H, Usuki K, Yokoyama K, Yamamoto K, Aotsuka N, Ishizawa K, Takezako N, Miyagishima T, Ishida T, Shinagawa A, Wakasa K, Nakamaki T, Tomita N, Ozaki K, Itoh T, Kowata S, Tajika K, Fujio T, Onozawa M, Yamamoto M, Kondo T, Najima Y, Iriyama N, Tsutsumi I, Oba K, Kojima H, Sakamaki H, Inokuchi K. Importance of the duration of TKI treatment in treatment-free remission of chronic phase chronic myeloid leukemia: results of D-Free trial. Blood. 2021;138:1477.","journal-title":"Blood"},{"issue":"6","key":"1444_CR25","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s12185-019-02736-5","volume":"110","author":"K Nagafuji","year":"2019","unstructured":"Nagafuji K, Matsumura I, Shimose T, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Kadowaki N, Ishikawa J, Imamura Y, Yamazaki H, Akashi K, Kanakura Y. Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt). Int J Hematol. 2019;110(6):675\u201382.","journal-title":"Int J Hematol"},{"issue":"1","key":"1444_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4103\/ijmr.ijmr_1090_21","volume":"157","author":"D Goni","year":"2023","unstructured":"Goni D, Jain A, Singh C, Jindal N, Nampoothiri R, Jandial A, Lad D, Khadwal A, Prakash G, Naseem S, Varma N, Malhotra P. Feasibility of treatment-free remission with generic imatinib: results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study. Indian J Med Res. 2023;157(1):87\u201391.","journal-title":"Indian J Med Res"},{"key":"1444_CR27","doi-asserted-by":"crossref","unstructured":"Shah NP, Garc\u00eda-Guti\u00e9rrez V, Jim\u00e9nez-Velasco A, Larson SM, Saussele S, Rea D, Mahon FX, Levy MY, G\u00f3mez-Casares MT, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH. Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: final 5-year analysis of DASFREE. Br J Haematol 2023.","DOI":"10.1111\/bjh.18883"},{"issue":"12","key":"1444_CR28","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.3324\/haematol.2022.280811","volume":"107","author":"S Dulucq","year":"2022","unstructured":"Dulucq S, Nicolini FE, Rea D, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, Coiteux V, Lenain P, Rigal-Huguet F, Liu JX, Guerci-Bresler A, Legros L, Ianotto JC, Gardembas M, Turlure P, Dubruille V, Rousselot P, Martiniuc J, Jardel H, Johnson-Ansah H, Joly B, Henni T, Cayssials E, Zunic P, Berger MG, Villemagne B, Robbesyn F, Morisset S, Mahon FX, Etienne G. Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial. Haematologica. 2022;107(12):2859\u201369.","journal-title":"Haematologica"},{"issue":"10","key":"1444_CR29","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.3324\/haematol.2021.280175","volume":"107","author":"G Gugliotta","year":"2022","unstructured":"Gugliotta G, Castagnetti F, Breccia M, Levato L, Intermesoli T, D\u2019Adda M, Salvucci M, Stagno F, Rege-Cambrin G, Tiribelli M, Martino B, Bocchia M, Cedrone M, Trabacchi E, Cavazzini F, Porretto F, Sor\u00e0 F, Simula MP, Albano F, Soverini S, Fo\u00e0 R, Pane F, Cavo M, Saglio G, Baccarani M, Rosti G. Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study. Haematologica. 2022;107(10):2356\u201364.","journal-title":"Haematologica"},{"issue":"1","key":"1444_CR30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jamaoncol.2020.5774","volume":"7","author":"E Atallah","year":"2021","unstructured":"Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, Ritchie EK, Silver RT, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, Horowitz M, Flynn KE. Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial. JAMA Oncol. 2021;7(1):42\u201350.","journal-title":"JAMA Oncol"},{"issue":"8","key":"1444_CR31","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1111\/cas.14518","volume":"111","author":"T Kumagai","year":"2020","unstructured":"Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, Takano H, Kouzai Y, Murase T, Matsue K, Morita S, Sakamoto J, Wakita H, Sakamaki H, Inokuchi K. Silent NK\/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment-free remission. Cancer Sci. 2020;111(8):2923\u201334.","journal-title":"Cancer Sci"},{"issue":"3","key":"1444_CR32","doi-asserted-by":"publisher","first-page":"E218","DOI":"10.1016\/S2352-3026(19)30235-2","volume":"7","author":"S Kimura","year":"2020","unstructured":"Kimura S, Imagawa J, Murai K, Hino M, Kitawaki T, Okada M, Tanaka H, Shindo M, Kumagai T, Ikezoe T, Uoshima N, Sato T, Watanabe R, Kowata S, Hayakawa M, Hosoki T, Ikeda K, Kobayashi T, Kakinoki Y, Nishimoto T, Takezako N, Shibayama H, Takaori-Kondo A, Nakamae H, Kawaguchi A, Ureshino H, Sakamoto J, Ishida Y, Grp DT. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2020;7(3):E218\u201325.","journal-title":"Lancet Haematol"},{"issue":"3","key":"1444_CR33","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s12185-019-02801-z","volume":"111","author":"H Yamaguchi","year":"2020","unstructured":"Yamaguchi H, Takezako N, Ohashi K, Oba K, Kumagai T, Kozai Y, Wakita H, Yamamoto K, Fujita A, Igarashi T, Yoshida C, Ohyashiki K, Okamoto S, Sakamoto J, Sakamaki H, Inokuchi K. Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group. Int J Hematol. 2020;111(3):401\u20138.","journal-title":"Int J Hematol"},{"issue":"11","key":"1444_CR34","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3324\/haematol.2018.194894","volume":"103","author":"N Takahashi","year":"2018","unstructured":"Takahashi N, Nishiwaki K, Nakaseko C, Aotsuka N, Sano K, Ohwada C, Kuroki J, Kimura H, Tokuhira M, Mitani K, Fujikawa K, Iwase O, Ohishi K, Kimura F, Fukuda T, Tanosaki S, Takahashi S, Kameoka Y, Nishikawa H, Wakita H, Grp SS. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. Haematologica. 2018;103(11):1835\u201342.","journal-title":"Haematologica"},{"issue":"4","key":"1444_CR35","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s10147-018-1368-2","volume":"24","author":"S Fujisawa","year":"2019","unstructured":"Fujisawa S, Ueda Y, Usuki K, Kobayashi H, Kondo E, Doki N, Nakao T, Kanda Y, Kosugi N, Kosugi H, et al. Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial). Int J Clin Oncol. 2019;24(4):445\u201353.","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"1444_CR36","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen J, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Str\u00f6mberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Pol\u00e1kov\u00e1 KM, M\u00fcller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX, Investigators E-S. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747\u201357.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1444_CR37","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/M17-1094","volume":"168","author":"FX Mahon","year":"2018","unstructured":"Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, Ailawadhi S, Lipton JH, Turkina AG, De Paz R, Moiraghi B, Nicolini FE, Dengler J, Sacha T, Takahashi N, Fellague-Chebra R, Acharya S, Wong S, Jin Y, Hughes TP. Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, Open-Label Study. Ann Intern Med. 2018;168(7):461\u201370.","journal-title":"Ann Intern Med"},{"issue":"2","key":"1444_CR38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12185-017-2334-x","volume":"107","author":"N Takahashi","year":"2018","unstructured":"Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, Miyata Y, Kobayashi S, Usuki K, Matsumura I, Minami Y, Usui N, Fukuda T, Takada S, Ishikawa M, Fujimaki K, Gomyo H, Sasaki O, Ohishi K, Miyake T, Imai K, Suzushima H, Mitsui H, Togitani K, Kiguchi T, Atsuta Y, Ohtake S, Ohnishi K, Kobayashi Y, Kiyoi H, Miyazaki Y, Naoe T, et al. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. Int J Hematol. 2018;107(2):185\u201393.","journal-title":"Int J Hematol"},{"issue":"6","key":"1444_CR39","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3324\/haematol.2015.139899","volume":"101","author":"SE Lee","year":"2016","unstructured":"Lee SE, Choi SY, Song HY, Kim SH, Choi MY, Park JS, Kim HJ, Kim SH, Zang DY, Oh S, Kim H, Do YR, Kwak JY, Kim JA, Kim DY, Mun YC, Lee WS, Chang MH, Park J, Kwon JH, Kim DW. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica. 2016;101(6):717\u201323.","journal-title":"Haematologica"},{"issue":"7","key":"1444_CR40","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/leu.2017.63","volume":"31","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, G\u00f3mez Casares MT, Hellmann A, Stentoft J, Conneally E, Garc\u00eda-Guti\u00e9rrez V, Gattermann N, Wiktor-Jedrzejczak W, le Coutre PD, Martino B, Saussele S, Menssen HD, Deng W, Krunic N, Bedoucha V, Saglio G. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31(7):1525\u201331.","journal-title":"Leukemia"},{"issue":"7","key":"1444_CR41","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","volume":"129","author":"D Rea","year":"2017","unstructured":"Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, Gardembas M, Coiteux V, Guillerm G, Legros L, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129(7):846\u201354.","journal-title":"Blood"},{"issue":"10","key":"1444_CR42","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/ajh.24120","volume":"90","author":"S Mori","year":"2015","unstructured":"Mori S, Vagge E, le Coutre P, Abruzzese E, Martino B, Pungolino E, Elena C, Pierri I, Assouline S, D\u2019Emilio A, Gozzini A, Giraldo P, Stagno F, Iurlo A, Luciani M, De Riso G, Redaelli S, Kim DW, Pirola A, Mezzatesta C, Petroccione A, Lodolo D\u2019Oria A, Crivori P, Piazza R, Gambacorti-Passerini C. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol. 2015;90(10):910\u20134.","journal-title":"Am J Hematol"},{"key":"1444_CR43","doi-asserted-by":"crossref","unstructured":"Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet BR, Gardembas M, Etienne G, Rea D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan AG, Guilhot J, Guilhot F, Mahon FX. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in CP-CML patients who have stopped imatinib after durable undetectable minimal residual disease. Blood 2013, 122 (21).","DOI":"10.1182\/blood.V122.21.381.381"},{"issue":"4","key":"1444_CR44","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, Mills AK, Melo JV, White DL, Grigg AP, Hughes TP. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515\u201322.","journal-title":"Blood"},{"issue":"6","key":"1444_CR45","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3324\/haematol.2011.056853","volume":"97","author":"N Takahashi","year":"2012","unstructured":"Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T, Usui N, Okamoto S, Ohe Y, Ohtake S, Kitamura K, Yamamoto M, Teshima H, Motoji T, Tamaki T, Sawada K, Ohyashiki K. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematol J. 2012;97(6):903\u20136.","journal-title":"Haematol J"},{"key":"1444_CR46","first-page":"119","volume":"40","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Saussele S, Baerlocher G, Br\u00fcmmendorf TH, Burchert A, Eigendorff E, Hasford J, Hehlmann R, Heim D, Krause S, Le Coutre P, La Ros\u00e9e P, Mayer J, Niederwieser D, H\u00e4nel M, Stegelmann F, Lange T, Ernst T, Sch\u00e4fer V, Fabisch C, Pfirrmann M. Nilotinib vs nilotinib plus interferon \u03b1 induction and nilotinib or interferon \u03b1 maintenance therapy for newly diagnosed BCR-ABL positive chronic myeloid leukemia patients in chronic phase: Interim analysis of the TIGER (CML V) study. Oncol Res Treatment. 2017;40:119\u201320.","journal-title":"Oncol Res Treatment"},{"issue":"9","key":"1444_CR47","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1182\/blood.2020005514","volume":"137","author":"N Shanmuganathan","year":"2021","unstructured":"Shanmuganathan N, Pagani IS, Ross DM, Park S, Yong ASM, Braley JA, Altamura HK, Hiwase DK, Yeung DT, Kim DW, Branford S, Hughes TP. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood. 2021;137(9):1196\u2013207.","journal-title":"Blood"},{"key":"1444_CR48","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.3324\/haematol.2017.180687","volume":"103","author":"G Colafigli","year":"2018","unstructured":"Colafigli G, Breccia M, Diverio D, Molica M, Loglisci MG, Guarini A, Foa R. Digital droplet PCR as a method to better identify chronic myeloid leukemia patients candidates to treatment-free remission. Haematologica. 2018;103:S94\u20135.","journal-title":"Haematologica"},{"issue":"3","key":"1444_CR49","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/ejh.13084","volume":"101","author":"WJ Wang","year":"2018","unstructured":"Wang WJ, Zheng CF, Liu Z, Tan YH, Chen XH, Zhao BL, Li GX, Xu ZF, Ren FG, Zhang YF, Chang JM, Wang HW. Droplet digital PCR for BCR\/ABL(P210) detection of chronic myeloid leukemia: a high sensitive method of the minimal residual disease and disease progression. Eur J Haematol. 2018;101(3):291\u20136.","journal-title":"Eur J Haematol"},{"key":"1444_CR50","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3324\/haematol.2018.204792","volume":"104","author":"M Ansuinelli","year":"2019","unstructured":"Ansuinelli M, Rosati S, Lisi C, Carmosino I, Diverio D, Scalzulli E, Bruzzese A, Porrazzo M, Mariggio E, Mohamed S, Molica M, Rizzo L, De Luca ML, Mancini M, Breccia M, Fo\u00e0 R, Latagliata R. Treatment-free remission in chronic myeloid leukemia patients with sustained deep molecular response who discontinued Tyrosine Kinase inhibitor treatment. Is real life better than clinical trials? Haematologica. 2019;104:143.","journal-title":"Haematologica"},{"issue":"8","key":"1444_CR51","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1038\/s41375-021-01173-w","volume":"35","author":"J Richter","year":"2021","unstructured":"Richter J, L\u00fcbking A, S\u00f6derlund S, Lotfi K, Markev\u00e4rn B, Sj\u00e4lander A, Stenke L, Deneberg S, Ahlstrand E, Myhr-Eriksson K, Panayiotidis P, Gedde-Dahl T, \u017d\u00e1\u010dkov\u00e1 D, Mayer J, Olsson-Str\u00f6mberg U, Mahon FX, Saussele S, Hjorth-Hansen H, Koskenvesa P. Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI. Leukemia. 2021;35(8):2416\u20138.","journal-title":"Leukemia"},{"key":"1444_CR52","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/01.HS9.0000559848.15284.8c","volume":"3","author":"DM Ross","year":"2019","unstructured":"Ross DM, Masszi T, G\u00f3mez Casares MT, Hellmann A, Stentoft J, Conneally E, Garc\u00eda Gutierrez V, Gattermann N, Le Coutre PD, Martino B, Saussele S, Giles FJ, Radich JP, Saglio G, Sondhi M, Acharyya S, Aimone P, Hochhaus A. Durability and impact on quality of life of treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) after stopping frontline (1L) nilotinib: ENESTfreedom 192-WK results. HemaSphere. 2019;3:157.","journal-title":"HemaSphere"},{"issue":"3","key":"1444_CR53","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","volume":"20","author":"D Vetrie","year":"2020","unstructured":"Vetrie D, Helgason GV, Copland M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat Rev Cancer. 2020;20(3):158\u201373.","journal-title":"Nat Rev Cancer"},{"key":"1444_CR54","doi-asserted-by":"publisher","first-page":"1194712","DOI":"10.3389\/fphar.2023.1194712","volume":"14","author":"P Pacelli","year":"2023","unstructured":"Pacelli P, Santoni A, Sicuranza A, Abruzzese E, Giai V, Crugnola M, Annunziata M, Galimberti S, Iurlo A, Luciano L, Sor\u00e0 F, Fava C, Bestoso E, Marzano C, Cartocci A, Defina M, Sammartano V, Cencini E, Raspadori D, Bocchia M. Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26(+) leukemia stem cells. Front Pharmacol. 2023;14:1194712.","journal-title":"Front Pharmacol"},{"key":"1444_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.84","author":"M Matsushita","year":"2017","unstructured":"Matsushita M, Ozawa K, Suzuki T, Nakamura M, Nakano N, Kanchi S, Ichikawa D, Matsuki E, Sakurai M, Karigane D, Kasahara H, Tsukamoto N, Shimizu T, Mori T, Nakajima H, Okamoto S, Kawakami Y, Hattori Y. CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients. Blood Cancer J. 2017. https:\/\/doi.org\/10.1038\/bcj.2017.84.","journal-title":"Blood Cancer J"},{"issue":"11","key":"1444_CR56","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1182\/bloodadvances.2022008854","volume":"7","author":"YD Irani","year":"2023","unstructured":"Irani YD, Kok CH, Clarson J, Shanmuganathan N, Branford S, Yeung DT, Ross DM, Hughes TP, Yong ASM. Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia. Blood Adv. 2023;7(11):2364\u201374.","journal-title":"Blood Adv"},{"issue":"8","key":"1444_CR57","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1038\/s41375-020-0867-0","volume":"34","author":"G Sharf","year":"2020","unstructured":"Sharf G, Marin C, Bradley JA, Pemberton-Whiteley Z, Bombaci F, Christensen RIO, Gouimi B, Deekes NB, Daban M, Geissler J. Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs. Leukemia. 2020;34(8):2102\u201312.","journal-title":"Leukemia"},{"issue":"1","key":"1444_CR58","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/bjh.17807","volume":"196","author":"DDH Kim","year":"2022","unstructured":"Kim DDH, Kim TS, Atenafu EG, Novitzky Basso I, Forrest D, Bence-Bruckler I, Savoie L, Busque L, Keating MM, Delage R, Xenocostas A, Liew E, Paulson K, Stockley T, Laneuville P, Lipton JH, Kamel-Reid S, Leber B. BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase. Br J Haematol. 2022;196(1):136\u201345.","journal-title":"Br J Haematol"},{"issue":"6","key":"1444_CR59","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/leu.2015.45","volume":"29","author":"A Burchert","year":"2015","unstructured":"Burchert A, Saussele S, Eigendorff E, M\u00fcller MC, Sohlbach K, Inselmann S, Sch\u00fctz C, Metzelder SK, Ziermann J, Kostrewa P, Hoffmann J, Hehlmann R, Neubauer A, Hochhaus A. Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia. Leukemia. 2015;29(6):1331\u20135.","journal-title":"Leukemia"},{"key":"1444_CR60","doi-asserted-by":"publisher","first-page":"1154377","DOI":"10.3389\/fphar.2023.1154377","volume":"14","author":"A Iurlo","year":"2023","unstructured":"Iurlo A, Cattaneo D, Consonni D, Castagnetti F, Miggiano MC, Binotto G, Bonifacio M, Rege-Cambrin G, Tiribelli M, Lunghi F, Gozzini A, Pregno P, Abruzzese E, Capodanno I, Bucelli C, Pizzuti M, Artuso S, Iezza M, Scalzulli E, La Barba G, Maggi A, Russo S, Elena C, Scortechini AR, Tafuri A, Latagliata R, Caocci G, Bocchia M, Galimberti S, Luciano L, Fava C, Fo\u00e0 R, Saglio G, Rosti G, Breccia M. Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: updated results from a campus CML real-life study. Front Pharmacol. 2023;14:1154377.","journal-title":"Front Pharmacol"},{"issue":"7","key":"1444_CR61","doi-asserted-by":"publisher","first-page":"E375","DOI":"10.1016\/S2352-3026(19)30094-8","volume":"6","author":"RE Clark","year":"2019","unstructured":"Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, Byrne J, de Lavallade H, Osborne W, Robinson L, O\u2019Brien SG, Read L, Foroni L, Copland M. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematology. 2019;6(7):E375\u201383.","journal-title":"Lancet Haematology"},{"issue":"5","key":"1444_CR62","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/s41375-023-01888-y","volume":"37","author":"D R\u00e9a","year":"2023","unstructured":"R\u00e9a D, Boquimpani C, Mauro MJ, Minami Y, Allepuz A, Maheshwari VK, D\u2019Alessio D, Wu Y, Lawrance R, Narbutas S, Sharf G, Hochhaus A. Health-related quality of life of patients with resistant\/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial. Leukemia. 2023;37(5):1060\u20137.","journal-title":"Leukemia"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01444-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-024-01444-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01444-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T16:17:34Z","timestamp":1729700254000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-024-01444-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1444"],"URL":"https:\/\/doi.org\/10.1007\/s12672-024-01444-9","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"30 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"586"}}